Medtech Artrya breaks into UK market

Crawley-based medtech company Artrya's European expansion plans are officially under way, after being recognised as one of the UK Health Services’ preferred suppliers of AI software.

This morning, the company announced it was one of 11 international suppliers to be listed among a pre-qualified shortlist of approved suppliers from which public organisations, including 1,250 National Health Service hospitals in the UK, could commission services. 

Artrya earned a place on that list for its cloud-based software Salix Coronary Anatomy, which improves the detection and treatment of coronary artery disease.

The diagnostic support tool provides an automated report to clinicians within 15 minutes, including the biomarker understood to be the strongest predictor of heart attack.

Artrya’s managing director and co-founder John Barrington said the recognition further validated the company’s European commercialisation plans and was an international endorsement of Salix’s clinical credentials.

Artrya said it expected to be able to sell into the UK in mid-2022.

In Australia, market pilots of Salix are under way in Perth and Sydney, with plans for a national launch flagged for early 2022.

The news comes just weeks after the company lodged a prospectus with the Australian Securities and Investments Commission in a bid to commence trading on the ASX by late November.

Artrya sought $40 million through an IPO to assist with the development and commercialisation of its software, one the company said had been well supported.